Olympic Ophthalmics

Olympic Ophthalmics is a commercial-stage private company that has developed and launched the iTEAR®100, a novel, drug-free medical device for dry eye disease. The device represents a unique neuromodulation approach in a market dominated by pharmaceuticals and lubricants, offering a potential long-term management solution. The company leverages a prescription-based, direct-to-patient sales model supported by telehealth services. Its leadership includes experienced medical device investors and executives, positioning it to capture share in the large and growing dry eye market.

External nasal neurostimulation device designed to activate the natural tear reflex pathway, increasing basal tear production.

The dry eye treatment market is highly competitive, dominated by large pharmaceutical companies (e.g., Allergan/AbbVie, Novartis) offering prescription drugs and OTC artificial tears. Olympic's iTEAR®100 competes as a neuromodulation device in a niche segment, differentiating on its drug-free mechanism but facing challenges in market education and reimbursement.